Prosecutors unsealed an additional charge of conspiracy to commit securities fraud against Martin Shkreli – infamously known for hiking up the price of a toxoplasmosis medicine by 5,000% – bringing the total number of criminal counts against the former drug company CEO to eight.
Former pharmaceutical company CEO Martin Shkreli – once dubbed the most hated man in America for hiking up the price of a toxoplasmosis drug last year by 5,000% – has racked up another criminal charge, which could add to the possible jail time he's already facing with the earlier seven counts, including securities fraud, brought against him this past December.
In a superseding indictment filed in the US District Court for the Southern District of New York, which was unsealed...
Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.
Many assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.
The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.
Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.
Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
